NCT01809184View on ClinicalTrials.gov

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 4, 2013

Primary Completion Date

September 6, 2013

Study Completion Date

September 6, 2013

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin 287

Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.

DRUG

insulin glargine

Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.

DRUG

placebo

Oral placebo adminstered corresponding to insulin 287 treatment

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01809184 - A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects | Biotech Hunter | Biotech Hunter